The first study examines TNF-a levels in patients receiving the GLP-1 agonist Wegovy ® or Ozempic ® who show signs of increased inflammation associated with sarcopenia, which is the progressive loss ...

In fact, rates of adverse events such as respiratory hospitalization, death from lung disease, and all-cause mortality were numerically higher in the non-TNF inhibitor users -- hazard ratios ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...

TNF inhibitor users had a lower risk for hip and spine fractures (adjusted odds ratio [aOR], 0.75; 95% CI, 0.62-0.91) than NSAID users, but this protective association was not seen in csDMARD users.

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...

Whereas the trial's original primary analysis showed roughly double the MACE risk with tofacitinib as compared with TNF blockers, when the JAK inhibitor group was stratified according to statin ...

TNF Pharmaceuticals (TNFA) announced that it has achieved a safety data milestone supporting expanded and longer-term clinical studies of its ...